Global Alzheimers Disease Drug
Market Report
2025
Delivery Includes:- Market Timeline 2021 till 2033, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Alzheimers Disease Drug Market Report 2025.
In Terms of Revenue, Late-Onset was the Leading segment with 69.36% Share of total Alzheimers Disease Drug Market in 2021.
In Terms of Revenue, Cholinesterase Inhibitors was the Leading segment with 57.25% Share of total Alzheimers Disease Drug Market in 2021.
In Terms of Revenue, Hospital was the Leading segment with 46.14% Share of total Alzheimers Disease Drug Market in 2021.
In Terms of Revenue, Oral was the Leading segment with 62.14% Share of total Alzheimers Disease Drug Market in 2021.
North America was the dominated region with 41.23% of total revenue market share in 2021.
2021 | 2025 | 2033 | CAGR | |
---|---|---|---|---|
Global Market Size | 121212 | 121212 | 121212 | 121212 |
Country Market Size | 121212 | 121212 | 121212 | 121212 |
North Americ Market Size | 121212 | 121212 | 121212 | 121212 |
Europe Market Size | 121212 | 121212 | 121212 | 121212 |
Asia Pacific Market Size | 121212 | 121212 | 121212 | 121212 |
South America Market Size | 121212 | 121212 | 121212 | 121212 |
Middle East and Africa Market Size | 121212 | 121212 | 121212 | 121212 |
Base Year | 2024 |
Historical Data Time Period | 2021-2024 |
Forecast Period | 2025-2033 |
Market Split by Type |
|
Market Split by Application |
|
Market Split by Type of Disease |
|
Market Split by Drugs Type |
|
Market Split by Product |
|
Market Split by End-Users |
|
Market Split by Route of Administration |
|
Market Split by Distribution Channel |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Alzheimers Disease Drug industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Alzheimers Disease Drug Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Alzheimer's disease is a brain disease that causes memory loss and other cognitive impairment. It slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. Initially it only affects entorhinal cortex and hippocampus, but later affects areas in the cerebral cortex, such as those responsible for language, reasoning, and social behavior. Eventually, many other areas of the brain are damaged.
It has been suggested that more than 6 million Americans age 65 and older may have Alzheimer’s. Many more under age 65 also have the disease. Though there is no solid cure for Alzheimer’s disease, but significant progress in recent years in developing and testing new treatments has been done. Several medicines have been approved by the U.S. Food and Drug Administration to treat people with Alzheimer’s. This report will provide detailed analysis on Alzheimer's disease drugs.
Rising prevalence of Alzheimer’s disease:
Geriatric population is on the rise:
Current Trends on Alzheimer’s Disease Drug:
We have various report editions of Alzheimers Disease Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.
The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.
Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.
Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.
Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.
Eisai Co., Ltd. and Biogen Inc. completed the submission of Biologics License Application to U.S. Food and Drug Administration for lecanemab:
Eisai Co., Ltd. and Biogen Inc. announced that it has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.
AbbVie plans to move next-gen Aduhelm hopeful for Alzheimer's into the clinic
AbbVie has planned to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end or early next year. The company is pursuing a range of possible ways to tackle Alzheimer’s. Those include AL002, a monoclonal antibody trying to enhance the activity of the TREM2 gene, and AL003, which targets a genetic link to the disease, called sialic acid binding Ig-like lectin 3 (SIGLEC 3).
Novartis and Amgen have entered into collaboration with Banner Alzheimer's Institute
Novartis, Amgen and the Banner Alzheimer's Institute (BAI) has expanded collaboration in which the companies initiated a new trial - the Alzheimer's Prevention Initiative (API) Generation Study 2. This trial follows the launch of the Generation Study 1, and thus it determined whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms in a high-risk population.
Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease
Roche announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia, collectively called early Alzheimer’s disease. Gantenerumab was well tolerated, including the subcutaneous administration.
Top Companies Market Share in Alzheimers Disease Drug Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
As per our analysis, market share for Alzheimer’s Disease Drug in North America is over 40%. Hence North America is dominating the market with USD XX Bn in 2021. High number of people in America shows symptoms for Alzheimer’s disease and this number is continuously increasing. Thus, demand for AD drugs is significant in North America. Further, U.S. Food and Drug Administration approved Aduhelm recently for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
Two years of COVID-19 pandemic have shifted the dynamics in the US healthcare value chain. Innovation and growth continued unabated in services. acceleration of value-based care models and increasing application of technology across the healthcare industry are likely to continue in the long term. All these parameters driven North America market for Alzheimer’s Disease Drug.
Asia-Pacific Alzheimer’s Disease Drug market is set to show significant growth rate in coming years
Asia-Pacific Alzheimer’s Disease Drug market is set to display growth at a high compound annual growth rate as countries/territories on multiple metrics, New Zealand, Australia, Hong Kong, and Japan along with China and India has high potential for healthcare sector. Growing population, and increasing awareness has stimulated growth for this market. Further, like U.S., China and Japan are also experiencing growth in its geriatric population.
Alzheimer’s Disease Drug is also seeing a rapid rise in popularity in Europe, partly due to an overall growth in the European geriatric population.
The current report Scope analyzes Alzheimers Disease Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Global Alzheimers Disease Drug Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Alzheimers Disease Drug Industry growth. Alzheimers Disease Drug market has been segmented with the help of its Type, Application Type of Disease, and others. Alzheimers Disease Drug market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
This report categorizes competitors in the pharmaceutical and healthcare market based on their product offerings and business models. It includes key details such as definitions, benefits, applications, technological advancements, and regional advantages for each type of pharmaceutical product, including small molecule drugs, biologics, and biosimilars.
Market growth figures, such as market share percentages, revenue, and growth rates (e.g., CAGR), are provided for each segment over the specified period (2019-2023). The report covers various segments
Type of Alzheimers Disease Drug analyzed in this report are as follows:
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Alzheimers Disease Drug Industry. Request a Free Sample PDF!
This report analyzes revenue growth in the pharma and healthcare industry at global, regional, and national levels, highlighting trends and opportunities for each application. It explores how sectors like pharmaceuticals, therapy, and healthcare monitoring use innovations to address healthcare needs. Key factors include market size, revenue contributions, technological advancements (e.g., AI-driven diagnostics), and regulatory considerations. The report also covers the value chain, identifying key players and processes within the industry. For more information, please request a sample or contact our research team.
Some of the key Application of Alzheimers Disease Drug are:
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Late-onset Alzheimer's is the most common form of the disease, which happens to people ages 65 and older. Familial Alzheimer's disease is a form of Alzheimer's disease which is linked to genes. In families that are affected, members of at least two generations have had the disease. FAD makes up less than 1% of all cases of Alzheimer's.
Cholinesterase inhibitors are most prescribed type of drugs to treat symptoms related to memory, thinking, language, judgment and other thought processes. These medications prevent the breakdown of acetylcholine, a chemical messenger important for memory and learning. These drugs support communication between nerve cells. Thus, it held the largest revenue share of over 57%.
In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc., for the treatment of patients with severe dementia of Alzheimer’s disease (AD).
Hospitals dominates the end-user segment of Alzheimer’s Disease Drug in year 2021. However, homecare will show high growth rate in near future as 90% of Americans ages 65 and older want to stay at home for as long as possible, and this age group is growing rapidly. Moreover, home healthcare companies allow people who require extra care no matter what their age to remain in their homes, reducing the burden otherwise shouldered by healthcare facilities, hospitals, assisted living or rehabilitation centres, and nursing homes.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
The initial medication for Alzheimer's, Leqembi, is not being used widely because some medical professionals think there is no use in treating the condition that robs people of their memories. Since the medicine was approved by the US Food and medicine Administration, its requirements—which include frequent brain scans, twice-monthly infusions, and additional diagnostic tests—have contributed to its sluggish acceptance. Seven physicians who treat Alzheimer's patients said that their own hesitation to recommend Leqembi was due to worries about the medication's side effects, expense, and effectiveness. Alex Scott, the chief administrative officer of Eisai, admitted that doubts and the slower-than-anticipated adoption by major health systems had affected the launch. Over 6 million Americans are thought to be affected by the illness, and fewer than half of US neurologists advise patients to take Leqembi. Professor Michael Greicius of Stanford University's Centre for Memory Disorders stated that there is insufficient proof to support Leqembi's beneficial effects on patients. Other medical professionals have expressed worries about Leqembi's potential for brain haemorrhage and edoema, as well as the expense of the $26,500 yearly medication, regular MRIs, and twice-monthly injections.
Disclaimer:
Type | Centrally Acting AChE Inhibintors, NMDA Antagonists |
Application | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy |
Type of Disease | Early-Onset, Late-Onset, Familial |
Drugs Type | Cholinesterase Inhibitors, NMDA Receptor Antagonists |
Product | Donepezil, Galantamine, Rivastigmine, Memantine, Others |
End-Users | Hospitals, Specialty Clinics, Homecare |
Route of Administration | Oral, Parenteral |
Distribution Channel | Hospital Pharmacy, Retail Pharmacy, Online Stores, Others |
List of Competitors | Eisai, Pfizer, Novartis, Shire, Janssen, Forest Laboratories, H. Lundbeck, Merz, Daiichi Sankyo |
This chapter will help you gain GLOBAL Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review Global Alzheimers Disease Drug Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
This chapter will help you gain North America Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review North America Alzheimers Disease Drug Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
This chapter will help you gain Europe Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review Europe Alzheimers Disease Drug Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
This chapter will help you gain Asia Pacific Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review Asia Pacific Alzheimers Disease Drug Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
This chapter will help you gain South America Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review South America Alzheimers Disease Drug Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
This chapter will help you gain Middle East Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review Middle East Alzheimers Disease Drug Market Split by various segments and Country Split.
Chapter 6 Middle East Market Analysis
This chapter will help you gain Middle East Market Analysis of Alzheimers Disease Drug. Further deep in this chapter, you will be able to review Middle East Alzheimers Disease Drug Market Split by various segments and Country Split.
Chapter 7 Africa Market Analysis
This chapter provides an in-depth analysis of the market share among key competitors of Alzheimers Disease Drug. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Type of Disease Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Drugs Type Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by Product Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 15 Market Split by End-Users Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 16 Market Split by Route of Administration Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 17 Market Split by Distribution Channel Analysis 2021 - 2033
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Alzheimers Disease Drug market
Chapter 18 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Chapter 19 Research Methodology and Sources
Why Centrally Acting AChE Inhibintors have a significant impact on Alzheimers Disease Drug market? |
What are the key factors affecting the Centrally Acting AChE Inhibintors and NMDA Antagonists of Alzheimers Disease Drug Market? |
What is the CAGR/Growth Rate of Hospital Pharmacy during the forecast period? |
By type, which segment accounted for largest share of the global Alzheimers Disease Drug Market? |
Which region is expected to dominate the global Alzheimers Disease Drug Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|